Drug
Migalastat clinical trials
Also written Galafold, Lucerastat, ACT-434964 and OGT-923.
- studies test it
- 25
- open now
- 2
- in phase 3
- 11
- first study started
- 2002
Keep track of what changes. Save the migalastat studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
25 studies that test it; most in 2011 (5)
| Year | Studies |
|---|---|
| 2002 | 1 |
| 2003 | 1 |
| 2006 | 4 |
| 2007 | 1 |
| 2009 | 1 |
| 2011 | 5 |
| 2014 | 1 |
| 2015 | 2 |
| 2018 | 4 |
| 2019 | 2 |
| 2022 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 8
- Phase 2
- 6
- Phase 3
- 11
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 25 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses migalastat is read from its arms, and is right about nine times in ten.
Testing it · 25
- A Study of Migalastat in Pediatric Subjects (2 to <12 Yrs) With Fabry Disease and Amenable GLA VariantsRecruitingPhase 3Amicus TherapeuticsNCT06904261Written as Migalastat HCl 20 mg
- A Study to Learn How Well Lucerastat Works and How Safe it is in Untreated Adult Male Participants With Fabry DiseaseNot yet recruitingPhase 3Idorsia Pharmaceuticals Ltd.NCT07778667Written as Lucerastat
- A Study to Evaluate the Long-term Safety and Tolerability of Lucerastat in Adult Subjects With Fabry DiseaseActive, not recruitingPhase 3Idorsia Pharmaceuticals Ltd.NCT03737214Written as Lucerastat
- A Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal DiseaseActive, not recruitingPhase 3Amicus TherapeuticsNCT04020055Written as migalastat HCl 150 mg
- Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) With Fabry DiseaseCompletedPhase 3Amicus TherapeuticsNCT04049760Written as migalastat HCl 150 mg
- A Study to Assess the Safety, Tolerability and Pharmacokinetics of Lucerastat (CDP923) After Multiple Dosing in Healthy SubjectsCompletedPhase 1Idorsia Pharmaceuticals Ltd.NCT02944474Written as Lucerastat
- A Study to Assess the Safety and Pharmacokinetics of Lucerastat (OGT 923) in Healthy SubjectsCompletedPhase 1Idorsia Pharmaceuticals Ltd.NCT02944487Written as Lucerastat
- Efficacy and Safety of Lucerastat Oral Monotherapy in Adult Subjects With Fabry DiseaseCompletedPhase 3Idorsia Pharmaceuticals Ltd.NCT03425539Written as Lucerastat
- Effect of Cimetidine on the Pharmacokinetics of Lucerastat in Healthy SubjectsCompletedPhase 1Idorsia Pharmaceuticals Ltd.NCT03380455Written as Lucerastat
- Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged 12 to <18 Years)CompletedPhase 3Amicus TherapeuticsNCT03500094Written as Migalastat HCl 150 mg
- Open-Label Extension Study of the Long-Term Effects of Migalastat HCL in Patients With Fabry DiseaseCompletedPhase 3Amicus TherapeuticsNCT02194985Written as migalastat HCl 150 mg
- A Study in Healthy Subjects to Investigate Whether Administration of Lucerastat Can Affect Normal Heart FunctionCompletedPhase 1Idorsia Pharmaceuticals Ltd.NCT03832452Written as Lucerastat (Treatment A)
- Drug-Drug Interaction Study Between AT1001 (Migalastat Hydrochloride) and Agalsidase in Participants With Fabry DiseaseCompletedPhase 2Amicus TherapeuticsNCT01196871Written as Migalastat HCl
- Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry DiseaseCompletedPhase 3Amicus TherapeuticsNCT01218659Written as migalastat hydrochloride
- A 12-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry DiseaseCompletedPhase 2Amicus TherapeuticsNCT00283959Written as migalastat HCl
- Study of the Effects of Oral AT1001 (Migalastat Hydrochloride) in Patients With Fabry DiseaseCompletedPhase 3Amicus TherapeuticsNCT00925301Written as migalastat hydrochloride
- A Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry DiseaseCompletedPhase 2Amicus TherapeuticsNCT00214500Written as migalastat HCl
- A 12-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Female Participants With Fabry DiseaseCompletedPhase 2Amicus TherapeuticsNCT00304512Written as migalastat HCl
- Open-label Long-term Safety Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease Who Have Completed a Previous AT1001 StudyTerminatedPhase 2Amicus TherapeuticsNCT00526071Written as migalastat HCl
- Open-Label Phase 3 Long-Term Safety Study of MigalastatTerminatedPhase 3Amicus TherapeuticsNCT01458119Written as migalastat hydrochloride
See all 25 studies that test migalastat →
As the comparator · 1 — what is tested is compared with migalastat
Codes
What other systems call migalastat · ClinicalTrials.gg INT003808
- MeSH (NLM) C090092migalastatConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) C4XNY919FWMIGALASTATConfirmed FDA, NLM, Wikidata
- RxNorm 2054252Confirmed FDA, Wikidata
- Wikidata Q161613migalastatConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C78120MigalastatOne source FDA
- DrugBank DB05018One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C090092 | migalastat | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | C4XNY919FW | MIGALASTAT | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2054252 | — | Confirmed FDA, Wikidata |
| Wikidata | Q161613 | migalastat | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C78120 | Migalastat | One source FDA |
| DrugBank | DB05018 | — | One source Wikidata |
Also registered as lucerastat (UNII GVS3YDM418) and migalastat hydrochloride (UNII CLY7M0XD20 · RxNorm 2054264).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.